Several studies have demonstrated the benefit of anti-PD-(L)1 in combination with chemotherapy and studies are now investigating whether combined blockade of PD-(L)1 and TGF-β signaling can induce tumor regression [33–35]. The gene discussed is CD274; the disease is neoplasm.